291 related articles for article (PubMed ID: 30573406)
41. Adjunctive minocycline for major mental disorders: A systematic review.
Zheng W; Zhu XM; Zhang QE; Cheng G; Cai DB; He J; Ng CH; Ungvari GS; Peng XJ; Ning YP; Xiang YT
J Psychopharmacol; 2019 Oct; 33(10):1215-1226. PubMed ID: 31294649
[TBL] [Abstract][Full Text] [Related]
42. Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.
Kishi T; Mukai T; Matsuda Y; Iwata N
Neuromolecular Med; 2014 Mar; 16(1):61-9. PubMed ID: 23896722
[TBL] [Abstract][Full Text] [Related]
43. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia: A Randomized Clinical Trial.
Brown HE; Freudenreich O; Fan X; Heard SO; Goff D; Petrides G; Harrington AL; Kane JM; Judge H; Hoeppner B; Fava M; Perlis RH
JAMA Psychiatry; 2019 Jul; 76(7):691-699. PubMed ID: 30916714
[TBL] [Abstract][Full Text] [Related]
45. Adjunctive multi-session transcranial direct current stimulation for neurocognitive dysfunction in schizophrenia: A meta-analysis.
Sun CH; Jiang WL; Cai DB; Wang ZM; Sim K; Ungvari GS; Huang X; Zheng W; Xiang YT
Asian J Psychiatr; 2021 Dec; 66():102887. PubMed ID: 34740126
[TBL] [Abstract][Full Text] [Related]
46. Placebo-controlled augmentation trials of the antioxidant NAC in schizophrenia: A review.
Chen AT; Chibnall JT; Nasrallah HA
Ann Clin Psychiatry; 2016 Aug; 28(3):190-6. PubMed ID: 27490835
[TBL] [Abstract][Full Text] [Related]
47. Clozapine Augmentation With Antiepileptic Drugs for Treatment-Resistant Schizophrenia: A Meta-Analysis of Randomized Controlled Trials.
Zheng W; Xiang YT; Yang XH; Xiang YQ; de Leon J
J Clin Psychiatry; 2017 May; 78(5):e498-e505. PubMed ID: 28355041
[TBL] [Abstract][Full Text] [Related]
48. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
Ghajar A; Gholamian F; Tabatabei-Motlagh M; Afarideh M; Rezaei F; Ghazizadeh-Hashemi M; Akhondzadeh S
Hum Psychopharmacol; 2018 Jul; 33(4):e2662. PubMed ID: 29901250
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial.
Sepehrmanesh Z; Heidary M; Akasheh N; Akbari H; Heidary M
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Mar; 82():289-296. PubMed ID: 29126981
[TBL] [Abstract][Full Text] [Related]
50. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
[TBL] [Abstract][Full Text] [Related]
51. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial.
Chang JS; Ahn YM; Park HJ; Lee KY; Kim SH; Kang UG; Kim YS
J Clin Psychiatry; 2008 May; 69(5):720-31. PubMed ID: 18370574
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
[TBL] [Abstract][Full Text] [Related]
53. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial.
Zeinoddini A; Ahadi M; Farokhnia M; Rezaei F; Tabrizi M; Akhondzadeh S
J Psychiatr Res; 2014 Dec; 59():125-31. PubMed ID: 25227564
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
[TBL] [Abstract][Full Text] [Related]
55. Heterogeneity in response to repeated intranasal oxytocin in schizophrenia and autism spectrum disorders: A meta-analysis of variance.
Martins D; Paduraru M; Paloyelis Y
Br J Pharmacol; 2022 Apr; 179(8):1525-1543. PubMed ID: 33739447
[TBL] [Abstract][Full Text] [Related]
56. Intranasal Oxytocin May Improve High-Level Social Cognition in Schizophrenia, But Not Social Cognition or Neurocognition in General: A Multilevel Bayesian Meta-analysis.
Bürkner PC; Williams DR; Simmons TC; Woolley JD
Schizophr Bull; 2017 Oct; 43(6):1291-1303. PubMed ID: 28586471
[TBL] [Abstract][Full Text] [Related]
57. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
58. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and Safety of Adjunctive Aripiprazole in Schizophrenia: Meta-Analysis of Randomized Controlled Trials.
Zheng W; Zheng YJ; Li XB; Tang YL; Wang CY; Xiang YQ; de Leon J
J Clin Psychopharmacol; 2016 Dec; 36(6):628-636. PubMed ID: 27755219
[TBL] [Abstract][Full Text] [Related]
60. Intranasal Oxytocin for Negative Symptoms of Schizophrenia: Systematic Review, Meta-Analysis, and Dose-Response Meta-Analysis of Randomized Controlled Trials.
Sabe M; Zhao N; Crippa A; Strauss GP; Kaiser S
Int J Neuropsychopharmacol; 2021 Aug; 24(8):601-614. PubMed ID: 33890987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
